Neal C. Bradsher - 01 Jul 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director, 10%+ Owner
Signature
/s/ Neal C. Bradsher
Issuer symbol
LCTX
Transactions as of
01 Jul 2022
Net transactions value
$0
Form type
4
Filing time
06 Jul 2022, 16:15:34 UTC
Previous filing
01 Jul 2021
Next filing
03 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX OPTION TO PURCHASE COMMON SHARES Award $0 +50,000 $0.000000 50,000 01 Jul 2022 COMMON SHARES 50,000 $1.57 Direct F1, F2
holding LCTX OPTION TO PURCHASE COMMON SHARES 50,000 01 Jul 2022 COMMON SHARES 50,000 $2.86 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 40,000 01 Jul 2022 COMMON SHARES 40,000 $0.8263 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 40,000 01 Jul 2022 COMMON SHARES 40,000 $1.03 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 49,440 01 Jul 2022 COMMON SHARES 49,440 $1.67 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options will vest and become exercisable on July 1, 2023, provided, that Neal C. Bradsher (the "Reporting Person") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the "Issuer") on that date.
F2 These options were granted to the Reporting Person by the Issuer on July 1, 2022 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
F3 These options are currently exercisable.